Clinical Effects and Economic Impact of Dutasteride and Finasteride Therapy in Italian Men with Lower Urinary Tract Symptoms
December 2013
in “
Archivio italiano di urologia, andrologia
”
TLDR Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.
This study from 9 years ago compared the clinical effects and economic impact of dutasteride and finasteride therapy in Italian men with lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH). The study found that dutasteride was associated with a reduced likelihood of hospitalization for BPH-related surgery and newly detected prostate cancer compared to finasteride. The pharmacoeconomic analysis also suggested that the higher price of dutasteride may be offset by decreased medical resource consumption, resulting in a net budget impact in favor of dutasteride. However, the study was limited by its retrospective, non-randomized nature and the lack of information about symptomatic burden of the disease, urodynamic parameters, baseline PSA values, number and kind of core biopsies, and Gleason score. Further clinical trials are warranted to confirm these results and evaluate the long-term effectiveness of these drugs.